logo-loader
viewSynairgen PLC

“Not the end of the road” for Synairgen’s asthma treatment

Synairgen plc (LON:SNG) chief executive Richard Marsden tells Proactive Investors that it’s “not the end of the road” for its asthma treatment after AstraZeneca (LON:AZN) announced it would review how to proceed with the phase IIa trial of the drug.

AstraZeneca decided to stop the trial as fewer severe cases were found amongst patients than researchers had expected.

“It’s not the end of the road for the drug at all,” Marsden says.

The pharma giant will analyse the data generated so far in the trial at the start of next year, and Marsden thinks this could be a good thing.

“AstraZeneca [is] going to look at the data in the first quarter of next year, which is probably earlier than we had initially expected.”

“If anything, this is all happening earlier in the year than we had anticipated, so this could be good news.”

Quick facts: Synairgen PLC

Price: 41.5 GBX

AIM:SNG
Market: AIM
Market Cap: £61.94 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18

2 min read